Travere Therapeutics Highlights Growth Strategy and Pipeline Advances in Rare Kidney and Metabolic Diseases Presentation

Reuters01-17

Travere <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Highlights Growth <a href="https://laohu8.com/S/MSTR">Strategy</a> and Pipeline Advances in Rare Kidney and Metabolic Diseases Presentation

Travere Therapeutics Inc. has published a new presentation outlining its recent business developments and strategic priorities. The company reported significant growth in 2025, including a 143% year-over-year increase in U.S. net product sales for FILSPARI® and total net product sales of approximately $410 million. Travere highlighted progress in rare kidney and metabolic diseases, with efforts to solidify FILSPARI’s position in the IgAN market and ongoing regulatory review for its use in FSGS. The company also announced plans to restart the pivotal HARMONY study for pegtibatinase in the first quarter of 2026 following manufacturing process optimization, and ended 2025 with approximately $323 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on January 16, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604794317?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-17 12:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604794317","market":"fut","top_or_hot":-1,"title":"Travere Therapeutics Highlights Growth Strategy and Pipeline Advances in Rare Kidney and Metabolic Diseases Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Highlights Growth <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> and Pipeline Advances in Rare Kidney and Metabolic Diseases Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Travere Therapeutics Inc. has published a new presentation outlining its recent business developments and strategic priorities. The company reported significant growth in 2025, including a 143% year-over-year increase in U.S. net product sales for FILSPARI® and total net product sales of approximately $410 million. Travere highlighted progress in rare kidney and metabolic diseases, with efforts to solidify FILSPARI’s position in the IgAN market and ongoing regulatory review for its use in FSGS. The company also announced plans to restart the pivotal HARMONY study for pegtibatinase in the first quarter of 2026 following manufacturing process optimization, and ended 2025 with approximately $323 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on January 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Travere Therapeutics Highlights Growth Strategy and Pipeline Advances in Rare Kidney and Metabolic Diseases Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTravere Therapeutics Highlights Growth Strategy and Pipeline Advances in Rare Kidney and Metabolic Diseases Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-17 12:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Highlights Growth <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> and Pipeline Advances in Rare Kidney and Metabolic Diseases Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Travere Therapeutics Inc. has published a new presentation outlining its recent business developments and strategic priorities. The company reported significant growth in 2025, including a 143% year-over-year increase in U.S. net product sales for FILSPARI® and total net product sales of approximately $410 million. Travere highlighted progress in rare kidney and metabolic diseases, with efforts to solidify FILSPARI’s position in the IgAN market and ongoing regulatory review for its use in FSGS. The company also announced plans to restart the pivotal HARMONY study for pegtibatinase in the first quarter of 2026 following manufacturing process optimization, and ended 2025 with approximately $323 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on January 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260117:nNDL7BHn5K:1","article_id":"2604794317","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604794317","pubTimestamp":1768622853,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Travere Therapeutics Inc. has published a new presentation outlining its recent business developments and strategic priorities. The company reported significant growth in 2025, including a 143% year-over-year increase in U.S. net product sales for FILSPARI and total net product sales of approximately $410 million. Travere highlighted progress in rare kidney and metabolic diseases, with efforts to solidify FILSPARI’s position in the IgAN market and ongoing regulatory review for its use in FSGS. The company also announced plans to restart the pivotal HARMONY study for pegtibatinase in the first quarter of 2026 following manufacturing process optimization, and ended 2025 with approximately $323 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVTX":"Travere Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Travere Therapeutics重点介绍罕见肾脏和代谢疾病的增长战略和管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":0.9},"content_text":"Travere Therapeutics Highlights Growth Strategy and Pipeline Advances in Rare Kidney and Metabolic Diseases Presentation\n    \n\n        Travere Therapeutics Inc. has published a new presentation outlining its recent business developments and strategic priorities. The company reported significant growth in 2025, including a 143% year-over-year increase in U.S. net product sales for FILSPARI® and total net product sales of approximately $410 million. Travere highlighted progress in rare kidney and metabolic diseases, with efforts to solidify FILSPARI’s position in the IgAN market and ongoing regulatory review for its use in FSGS. The company also announced plans to restart the pivotal HARMONY study for pegtibatinase in the first quarter of 2026 following manufacturing process optimization, and ended 2025 with approximately $323 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on January 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604794317","isCrawlerRequest":true}